Hormone treatment only for older ER-positive breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This Phase 2 study tests whether using hormone (endocrine) treatment alone can control breast cancer in people age 70 and older. It targets breast cancers that are estrogen-receptor positive and HER2 negative, aiming to avoid chemotherapy-like treatments in suitable patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 70 years old or older
- Your breast cancer is newly diagnosed and can be treated with surgery (operable invasive cancer)
- Your tumor is estrogen-receptor positive (ER+) and HER2 negative (HER2-)
- Your cancer’s growth marker is low (Ki-67/proliferation score is 30% or less, or mitotic index is low to intermediate)
- You have at least one measurable spot on imaging that can be measured by ultrasound or mammogram
- You have not had surgery for this cancer yet, and you can follow study visits (ECOG health/activity score 3 or less)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at the potential harms and benefits of hormone (endocrine) therapy in people age 70 and older with early-stage, hormone-receptor–positive breast cancer. It may help doctors choose which hormone treatment approach is safest and most helpful for older patients.
This Phase 3 trial compares hormone-based treatment versus chemotherapy given before surgery in people who are premenopausal and have hormone-receptor positive, HER2-negative breast cancer. It looks to see which approach works better to control the cancer before the breast operation.
This Phase 2 study tests a combination of immune-based treatments along with hormone (endocrine) therapy to slow or shrink advanced, hormone-receptor positive, HER2-negative breast cancer. You may be a candidate if your cancer has progressed after standard hormone-blocking medicines and you can start treatment with CDK4/6 medicine plus an aromatase inhibitor.
This trial tests a new oral drug (HRS-8080) against standard hormone therapy for women with intermediate- or high-risk early breast cancer who have already completed 2 to 5 years of hormone treatment. It aims to see if the new drug can reduce the risk of cancer coming back.
This trial is testing how well a short course of hormone-blocking pills (endocrine therapy) works before surgery in women with early-stage hormone receptor-positive HER2-negative breast cancer. The goal is to understand what makes some cancers resistant to these treatments.
This trial tests if taking hormone therapy for 5 more years helps prevent breast cancer from coming back. It is for women who have already completed 5 years of tamoxifen or an aromatase inhibitor and had lymph node involvement at diagnosis.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.